Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data
OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ulcerative colitis candidate lusvertikimab.
Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data Read More »
